



**Final Appraisal Recommendation**  
Advice No: 1117 – June 2017

**Aviptadil/phentolamine mesilate (Invicorp®) 25 micrograms/  
2 mg solution for injection**

**Resubmission by Evolan Pharma AB**

**Recommendation of AWMSG**

**Aviptadil/phentolamine (Invicorp®) is recommended as an option for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.**

**Aviptadil/phentolamine (Invicorp®) is restricted to use in people with erectile dysfunction that has not responded to oral PDE5 inhibitor therapy.**

**Aviptadil/phentolamine (Invicorp®) is not recommended for use within NHS Wales outside of this subpopulation.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3435), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Evolan Pharma AB
Date of first issue	June 2017
Last reviewed	September 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1117:  
Aviptadil phentolamine (Invicorp®) 25 micrograms/  
2 mg solution for injection June 2017



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>